These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12929324)

  • 1. [Positive list of drugs and osteoporosis].
    Krankenpfl J; 2003; 41(4-6):113. PubMed ID: 12929324
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
    Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
    [No Abstract]   [Full Text] [Related]  

  • 3. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
    Harder Yv
    Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
    [No Abstract]   [Full Text] [Related]  

  • 4. [Legal boundaries of negative and positive lists].
    Arndt M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):630-2. PubMed ID: 9527457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Open letter to minister of health. Toad medicine].
    Erdmann E
    Krankenpfl J; 2003; 41(4-6):110-1. PubMed ID: 12929321
    [No Abstract]   [Full Text] [Related]  

  • 6. [Does red-green destroy phytotherapy?].
    Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
    [No Abstract]   [Full Text] [Related]  

  • 7. [Off-label use in psychopharmacotherapy. Letter to Federal Minister Ulla Schmidt, Pulheim, 22 January 2003].
    Fritze J
    Nervenarzt; 2003 Apr; 74(4):389; discussion 390. PubMed ID: 12800838
    [No Abstract]   [Full Text] [Related]  

  • 8. [No reimbursement for non-prescription medicine. Expensive savings plan?].
    MMW Fortschr Med; 2003 Aug; 145(33-34):57. PubMed ID: 14526581
    [No Abstract]   [Full Text] [Related]  

  • 9. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
    Thöns M
    MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
    [No Abstract]   [Full Text] [Related]  

  • 10. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 11. [The significance of the list of prescribable drugs (so-called positive list) for psychopharmacotherapy].
    Fritze J; Schmauss M; Holsboer F;
    Nervenarzt; 2003 Feb; 74(2):195-7. PubMed ID: 12683388
    [No Abstract]   [Full Text] [Related]  

  • 12. [An end to scurrilous recommendations on the new regulation. What is still allowed on the insurance form?].
    Schmidt K
    MMW Fortschr Med; 2004 Apr; 146(15):60-2. PubMed ID: 15373023
    [No Abstract]   [Full Text] [Related]  

  • 13. Can a health care system change?
    Lexchin J
    CMAJ; 1997 Sep; 157(5):507-8. PubMed ID: 9294383
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prescribing fictitiously approved drugs: regress threatens!].
    Walbert H
    MMW Fortschr Med; 2012 Apr; 154(6):10. PubMed ID: 22642016
    [No Abstract]   [Full Text] [Related]  

  • 15. [The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
    Hellmich B; Gross WL
    Z Rheumatol; 2003 Feb; 62(1):34-5. PubMed ID: 12624800
    [No Abstract]   [Full Text] [Related]  

  • 16. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Routine osteoporosis therapy].
    Ringe JD
    Krankenpfl J; 2004; 42(7-10):233. PubMed ID: 15675395
    [No Abstract]   [Full Text] [Related]  

  • 18. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly.
    Liu SZ; Romeis JC
    Health Policy; 2004 Jun; 68(3):277-87. PubMed ID: 15113639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finance issue brief: mandated benefits: osteoporosis coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-4. PubMed ID: 14870744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.